Markets

Bristol Myers Squibb Presents Interim Safety, Efficacy Data From Its Multiple Sclerosis Groups Of Phase 1 Trial Of Zolacabtagene Autoleucel At MSToronto 2026

Oct 23, 2026 · 10:33 AM ET· updated 1h ago

Bristol Myers Squibb (NYSE:BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2 study evaluating

Why It Matters

Bristol Myers Squibb shared early test results from a new multiple sclerosis medicine. When a company releases positive safety data from early trials, it hints the drug might move forward to the next testing stage.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

BMY61.79

-1.21 (-1.92%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.